Last updated: November 2026
My father died of Creutzfeldt-Jakob disease. The personal part of this is here.
What follows is what the research looks like now.
Most infectious diseases have a genome. A bacterium, a virus, a fungus - each carries instructions for making more of itself. A prion does not. It is a misfolded version of a protein the body already makes, called PrP (prion protein). The normal protein, PrPC, sits on the surface of neurons, largely folded into helices. The disease form, PrPSc, is mostly beta sheet. When PrPSc touches PrPC, it templates it into the misfolded shape. The new copy then does the same thing to the next one.
That is the whole mechanism. No nucleic acid, no replication machinery, just a shape that propagates. Stanley Prusiner proposed it in 1982 and it earned him the 1997 Nobel Prize in Physiology or Medicine, and it remains one of the stranger facts in biology: a protein that is infectious by conformation alone.
PrPSc does not get cleared the way ordinary misfolded proteins do. It is resistant to proteases, it accumulates, and the neurons around it die. The brain becomes spongy; that is the "spongiform" in transmissible spongiform encephalopathy. Once symptoms start, the decline is usually measured in months, not years. For sporadic CJD, the most common form, death typically comes within four months to two years of onset.
PRNP, the
gene for PrP. It includes familial CJD, Gerstmann-Sträussler-Scheinker
disease, and fatal familial insomnia.The same protein misfolds in animals: scrapie in sheep and goats, BSE in cattle, and chronic wasting disease (CWD) in deer, elk, and moose. CWD is the one spreading fastest, and it is now present across much of North America. Prions shed into soil by infected animals stay infectious for years.
For decades, prion disease looked untreatable for structural reasons, not just of effort. The infectious agent has no enzymes to inhibit, no genome to interfere with, no metabolism to poison. It is your own protein, folded wrong. There was nothing to attack that wasn't also you.
The other problem is timing. By the time symptoms appear, substantial neuronal loss has already happened. Anything that only slows the process is starting from a deep deficit.
The pivot is a single observation that turned out to be decisive. Mice with the
Prnp gene knocked out do not get prion disease. If the body does not make the
normal protein, the misfolded form has nothing to convert. PrP is the substrate
of the entire process.
That makes PrP itself a drug target. Lower the amount of PrP the brain produces, and you starve the reaction. Everything in the clinic right now is a variation on that idea.
In April 2026, the Broad Institute announced the first human trial of PrP-siRNA, a new drug designed to lower PrP. The trial is called PRiSM, and the drug is PrP-siRNA, a "divalent" small interfering RNA, meaning two siRNA molecules linked together so they distribute more widely through brain tissue. It is delivered by intrathecal injection, a lumbar puncture, because it cannot cross the blood-brain barrier on its own.
Inside the cell, the siRNA finds the RNA instructions for PrP and cuts them, so less protein gets made. In mice, a version of it lowered brain PrP to 49% of normal levels, and a single dose given after symptoms began increased survival time by 64%.
The trial is small: about 45 participants, including some people at genetic risk who do not yet have symptoms, enrolling one dose level at a time, escalating from 50 to 100 to 200 milligrams, each participant receiving a single dose. There is no placebo arm. Instead, when enrollment pauses between dose levels, patients who would have been screened are offered a parallel observational arm, so there is still a comparison group without giving anyone a placebo.
The investigators, Sonia Vallabh and Eric Minikel, are wife and husband. Vallabh learned in 2011 that she carries the genetic mutation that causes prion disease; she and Minikel changed careers to work on it. They have published their entire Investigational New Drug filing publicly, which is not how drug development is normally done.
What they say about their own trial is worth repeating plainly: most drugs that enter clinical trials fail, the first drug is usually not a cure, and there is no human data yet to suggest this one helps anyone. If it works at all, the mouse data suggest it slows further progression. It does not halt the disease and does not reverse damage already done.
PRiSM is not alone.
Lowering production via PrP supply is one lever. Other approaches are also actively researched:
This is not a treatment, but it may be the bottleneck.
For most of my life, CJD was a diagnosis with no next step. You learned the name, you learned there was nothing to be done, and that was the end of the conversation. My father's illness went the way the textbooks describe, because there was no other way for it to go.
What is different now is not that there is a cure. There isn't. What is different is that there is a target, a mechanism worth attacking, and drugs in people. The first ones will likely fail or disappoint. But the field has moved from "this is untreatable in principle" to "this is hard, and we are trying, and we know what we are trying."